PerkinElmer to Acquire BioLegend in $5.25-Billion Deal
PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.
PerkinElmer has entered into an agreement on July 26, 2021 to acquire BioLegend, a global developer and manufacturer of antibodies and reagents used in biomedical research (cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing). The transaction is expected to close by the end of 2021 and is valued at $5.25 billion.
With this acquisition, PerkinElmer will offer solutions in areas such as cell and gene therapy discovery. The company will also move into new spaces like proteogenomics. BioLegend’s new headquarters in San Diego, Calif. will serve as PerkinElmer’s center for research reagent content development.
Source: PerkinElmer
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
